Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.

Korecka JA, Thomas R, Christensen DP, Hinrich AJ, Ferrari EJ, Levy SA, Hastings ML, Hallett PJ, Isacson O.

Hum Mol Genet. 2019 Jul 1. pii: ddz126. doi: 10.1093/hmg/ddz126. [Epub ahead of print]

PMID:
31261377
2.

Neurite Collapse and Altered ER Ca2+ Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation.

Korecka JA, Talbot S, Osborn TM, de Leeuw SM, Levy SA, Ferrari EJ, Moskites A, Atkinson E, Jodelka FM, Hinrich AJ, Hastings ML, Woolf CJ, Hallett PJ, Isacson O.

Stem Cell Reports. 2019 Jan 8;12(1):29-41. doi: 10.1016/j.stemcr.2018.11.021. Epub 2018 Dec 27.

3.

Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age.

Brekk OR, Moskites A, Isacson O, Hallett PJ.

Sci Rep. 2018 Oct 12;8(1):15207. doi: 10.1038/s41598-018-33474-z.

4.

The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress.

Moloney EB, Moskites A, Ferrari EJ, Isacson O, Hallett PJ.

Neurobiol Dis. 2018 Dec;120:1-11. doi: 10.1016/j.nbd.2018.08.013. Epub 2018 Aug 24.

PMID:
30149180
5.

Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain.

Hallett PJ, Huebecker M, Brekk OR, Moloney EB, Rocha EM, Priestman DA, Platt FM, Isacson O.

Neurobiol Aging. 2018 Jul;67:189-200. doi: 10.1016/j.neurobiolaging.2018.02.028. Epub 2018 Mar 29.

6.

Increased motor neuron resilience by small molecule compounds that regulate IGF-II expression.

Osborn TM, Beagan J, Isacson O.

Neurobiol Dis. 2018 Feb;110:218-230. doi: 10.1016/j.nbd.2017.11.002. Epub 2017 Nov 4.

7.

Integrated molecular landscape of Parkinson's disease.

Klemann CJHM, Martens GJM, Sharma M, Martens MB, Isacson O, Gasser T, Visser JE, Poelmans G.

NPJ Parkinsons Dis. 2017 Apr 10;3:14. doi: 10.1038/s41531-017-0015-3. eCollection 2017.

8.

The Threshold Theory for Parkinson's Disease.

Engelender S, Isacson O.

Trends Neurosci. 2017 Jan;40(1):4-14. doi: 10.1016/j.tins.2016.10.008. Epub 2016 Nov 25. Review.

PMID:
27894611
9.

Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias.

Kordower JH, Vinuela A, Chu Y, Isacson O, Redmond DE Jr.

J Comp Neurol. 2017 Feb 15;525(3):498-512. doi: 10.1002/cne.24081. Epub 2016 Aug 29.

PMID:
27418401
10.

hVMAT2: A Target of Individualized Medication for Parkinson's Disease.

Xiong N, Li N, Martin E, Yu J, Li J, Liu J, Lee DY, Isacson O, Vance J, Qing H, Wang T, Lin Z.

Neurotherapeutics. 2016 Jul;13(3):623-34. doi: 10.1007/s13311-016-0435-5.

11.

Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease.

Wang X, Li N, Xiong N, You Q, Li J, Yu J, Qing H, Wang T, Cordell HJ, Isacson O, Vance JM, Martin ER, Zhao Y, Cohen BM, Buttner EA, Lin Z.

Mol Neurobiol. 2017 May;54(4):2878-2888. doi: 10.1007/s12035-016-9861-y. Epub 2016 Mar 28.

PMID:
27021023
12.

Gene therapy by proteasome activator, PA28γ, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.

Jeon J, Kim W, Jang J, Isacson O, Seo H.

Neuroscience. 2016 Jun 2;324:20-8. doi: 10.1016/j.neuroscience.2016.02.054. Epub 2016 Mar 2.

PMID:
26944602
13.

α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models.

Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1931-6. doi: 10.1073/pnas.1520335113. Epub 2016 Feb 2.

14.

In vivo modeling of neuronal function, axonal impairment and connectivity in neurodegenerative and neuropsychiatric disorders using induced pluripotent stem cells.

Korecka JA, Levy S, Isacson O.

Mol Cell Neurosci. 2016 Jun;73:3-12. doi: 10.1016/j.mcn.2015.12.004. Epub 2015 Dec 10. Review.

15.

Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.

Smith GA, Jansson J, Rocha EM, Osborn T, Hallett PJ, Isacson O.

Mol Neurobiol. 2016 Oct;53(8):5161-77. doi: 10.1007/s12035-015-9435-4. Epub 2015 Sep 23.

16.

Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.

Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, Beagan J, McLean JR, Izen SC, Perez-Torres E, Hallett PJ, Isacson O.

Neurobiol Dis. 2015 Oct;82:495-503. doi: 10.1016/j.nbd.2015.09.009. Epub 2015 Sep 25.

17.

Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.

Rocha EM, Smith GA, Park E, Cao H, Graham AR, Brown E, McLean JR, Hayes MA, Beagan J, Izen SC, Perez-Torres E, Hallett PJ, Isacson O.

Antioxid Redox Signal. 2015 Aug 20;23(6):550-64. doi: 10.1089/ars.2015.6307. Epub 2015 Jul 29.

18.

Lysosomes to combat Parkinson's disease.

Isacson O.

Nat Neurosci. 2015 Jun;18(6):792-3. doi: 10.1038/nn.4027. No abstract available.

PMID:
26007211
19.

Progressive decline of glucocerebrosidase in aging and Parkinson's disease.

Rocha EM, Smith GA, Park E, Cao H, Brown E, Hallett P, Isacson O.

Ann Clin Transl Neurol. 2015 Apr;2(4):433-8. doi: 10.1002/acn3.177. Epub 2015 Feb 6.

20.

Sorting the wheat from the chaff in dopamine neuron-based cell therapies.

Isacson O.

Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4512-3. doi: 10.1073/pnas.1503859112. Epub 2015 Apr 6. No abstract available.

21.

A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).

Smith GA, Rocha EM, Rooney T, Barneoud P, McLean JR, Beagan J, Osborn T, Coimbra M, Luo Y, Hallett PJ, Isacson O.

PLoS One. 2015 Mar 27;10(3):e0121072. doi: 10.1371/journal.pone.0121072. eCollection 2015.

22.

Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease.

Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, Sundberg M, Moore MA, Perez-Torres E, Brownell AL, Schumacher JM, Spealman RD, Isacson O.

Cell Stem Cell. 2015 Mar 5;16(3):269-74. doi: 10.1016/j.stem.2015.01.018. Epub 2015 Feb 26.

23.

Long-term health of dopaminergic neuron transplants in Parkinson's disease patients.

Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O.

Cell Rep. 2014 Jun 26;7(6):1755-61. doi: 10.1016/j.celrep.2014.05.027. Epub 2014 Jun 6.

24.

ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress.

McLean JR, Smith GA, Rocha EM, Osborn TM, Dib S, Hayes MA, Beagan JA, Brown TB, Lawson TF, Hallett PJ, Robertson J, Isacson O.

Exp Neurol. 2014 Nov;261:217-29. doi: 10.1016/j.expneurol.2014.05.024. Epub 2014 Jun 4.

PMID:
24907400
25.

Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection.

McLean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ, Isacson O.

Neurosci Lett. 2014 Jul 25;576:73-8. doi: 10.1016/j.neulet.2014.05.044. Epub 2014 May 29.

26.

Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease.

Smith GA, Rocha EM, McLean JR, Hayes MA, Izen SC, Isacson O, Hallett PJ.

Hum Mol Genet. 2014 Sep 1;23(17):4510-27. doi: 10.1093/hmg/ddu166. Epub 2014 Apr 12.

PMID:
24728190
27.

Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95.

Zhang J, Saur T, Duke AN, Grant SG, Platt DM, Rowlett JK, Isacson O, Yao WD.

J Neurogenet. 2014 Mar-Jun;28(1-2):98-111. doi: 10.3109/01677063.2014.892486. Epub 2014 Apr 22.

28.

Advances in stem-cell--generated transplantation therapy for Parkinson's disease.

Sundberg M, Isacson O.

Expert Opin Biol Ther. 2014 Apr;14(4):437-53. doi: 10.1517/14712598.2014.876986. Review.

PMID:
24437368
29.

Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease.

Davies SE, Hallett PJ, Moens T, Smith G, Mangano E, Kim HT, Goldberg AL, Liu JL, Isacson O, Tofaris GK.

Neurobiol Dis. 2014 Apr;64:79-87. doi: 10.1016/j.nbd.2013.12.011. Epub 2013 Dec 31.

30.

LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.

Sanders LH, Laganière J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschon DE, Vangipuram M, Sundararajan R, Urnov FD, Langston JW, Gregory PD, Zhang HS, Greenamyre JT, Isacson O, Schüle B.

Neurobiol Dis. 2014 Feb;62:381-6. doi: 10.1016/j.nbd.2013.10.013. Epub 2013 Oct 19.

31.

Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.

Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, Moore M, Osborn T, Cooper O, Spealman R, Hallett P, Isacson O.

Stem Cells. 2013 Aug;31(8):1548-62. doi: 10.1002/stem.1415.

32.

Characterization and criteria of embryonic stem and induced pluripotent stem cells for a dopamine replacement therapy.

Cooper O, Parmar M, Isacson O.

Prog Brain Res. 2012;200:265-76. doi: 10.1016/B978-0-444-59575-1.00012-0. Review.

PMID:
23195423
33.

Stem cells for Parkinson's disease: advancing science but protecting patients.

Olanow CW, Isacson O.

Mov Disord. 2012 Oct;27(12):1475-7. doi: 10.1002/mds.25170. Epub 2012 Oct 2. No abstract available.

PMID:
23032987
34.

Creation of an open-access, mutation-defined fibroblast resource for neurological disease research.

Wray S, Self M; NINDS Parkinson's Disease iPSC Consortium; NINDS Huntington's Disease iPSC Consortium; NINDS ALS iPSC Consortium, Lewis PA, Taanman JW, Ryan NS, Mahoney CJ, Liang Y, Devine MJ, Sheerin UM, Houlden H, Morris HR, Healy D, Marti-Masso JF, Preza E, Barker S, Sutherland M, Corriveau RA, D'Andrea M, Schapira AH, Uitti RJ, Guttman M, Opala G, Jasinska-Myga B, Puschmann A, Nilsson C, Espay AJ, Slawek J, Gutmann L, Boeve BF, Boylan K, Stoessl AJ, Ross OA, Maragakis NJ, Van Gerpen J, Gerstenhaber M, Gwinn K, Dawson TM, Isacson O, Marder KS, Clark LN, Przedborski SE, Finkbeiner S, Rothstein JD, Wszolek ZK, Rossor MN, Hardy J.

PLoS One. 2012;7(8):e43099. doi: 10.1371/journal.pone.0043099. Epub 2012 Aug 27.

35.

The search for genetic mouse models of prodromal Parkinson's disease.

Smith GA, Isacson O, Dunnett SB.

Exp Neurol. 2012 Oct;237(2):267-73. doi: 10.1016/j.expneurol.2012.06.035. Epub 2012 Jul 14. Review.

PMID:
22819262
36.

Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.

Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, McLean JR, Carrillo-Reid L, Xie Z, Osborn T, Hargus G, Deleidi M, Lawson T, Bogetofte H, Perez-Torres E, Clark L, Moskowitz C, Mazzulli J, Chen L, Volpicelli-Daley L, Romero N, Jiang H, Uitti RJ, Huang Z, Opala G, Scarffe LA, Dawson VL, Klein C, Feng J, Ross OA, Trojanowski JQ, Lee VM, Marder K, Surmeier DJ, Wszolek ZK, Przedborski S, Krainc D, Dawson TM, Isacson O.

Sci Transl Med. 2012 Jul 4;4(141):141ra90. doi: 10.1126/scitranslmed.3003985.

37.

α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits.

Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O.

Neurobiol Dis. 2012 Aug;47(2):258-67. doi: 10.1016/j.nbd.2012.04.009. Epub 2012 Apr 19.

38.

Viral and inflammatory triggers of neurodegenerative diseases.

Deleidi M, Isacson O.

Sci Transl Med. 2012 Feb 15;4(121):121ps3. doi: 10.1126/scitranslmed.3003492. Review.

39.

Clinical translation of stem cells in neurodegenerative disorders.

Lindvall O, Barker RA, Brüstle O, Isacson O, Svendsen CN.

Cell Stem Cell. 2012 Feb 3;10(2):151-5. doi: 10.1016/j.stem.2012.01.009.

40.

Using stem cells and iPS cells to discover new treatments for Parkinson's disease.

Cooper O, Hallett P, Isacson O.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S14-6. doi: 10.1016/S1353-8020(11)70007-4. Review.

41.
42.

Oct4-induced reprogramming is required for adult brain neural stem cell differentiation into midbrain dopaminergic neurons.

Deleidi M, Cooper O, Hargus G, Levy A, Isacson O.

PLoS One. 2011;6(5):e19926. doi: 10.1371/journal.pone.0019926. Epub 2011 May 31.

43.

Development of histocompatible primate-induced pluripotent stem cells for neural transplantation.

Deleidi M, Hargus G, Hallett P, Osborn T, Isacson O.

Stem Cells. 2011 Jul;29(7):1052-63. doi: 10.1002/stem.662.

44.

Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease.

Tsui A, Isacson O.

J Neurol. 2011 Aug;258(8):1393-405. doi: 10.1007/s00415-011-6061-6. Epub 2011 May 5. Review.

PMID:
21544566
45.

The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration.

Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O.

J Neurosci. 2010 Dec 1;30(48):16091-101. doi: 10.1523/JNEUROSCI.2400-10.2010.

46.

Global gene expression profiling of somatic motor neuron populations with different vulnerability identify molecules and pathways of degeneration and protection.

Hedlund E, Karlsson M, Osborn T, Ludwig W, Isacson O.

Brain. 2010 Aug;133(Pt 8):2313-30. doi: 10.1093/brain/awq167.

47.

Being too inclusive about synuclein inclusions.

Isacson O, Mendez I.

Nat Med. 2010 Sep;16(9):960-1; author reply 961. doi: 10.1038/nm0910-960b. No abstract available.

PMID:
20823871
48.

Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats.

Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, Yow A, Soldner F, Hockemeyer D, Hallett PJ, Osborn T, Jaenisch R, Isacson O.

Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15921-6. doi: 10.1073/pnas.1010209107. Epub 2010 Aug 23.

49.

The hAPP-YAC transgenic model has elevated UPS activity in the frontal cortex similar to Alzheimer's disease and Down's syndrome.

Seo H, Isacson O.

J Neurochem. 2010 Sep;114(6):1819-26. doi: 10.1111/j.1471-4159.2010.06902.x. Epub 2010 Aug 3.

50.

Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid.

Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E, Lee K, Levy A, Perez-Torres E, Yow A, Isacson O.

Mol Cell Neurosci. 2010 Nov;45(3):258-66. doi: 10.1016/j.mcn.2010.06.017. Epub 2010 Jul 24.

Supplemental Content

Loading ...
Support Center